A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.
Clinical trial NCT05630066 · COMPLETED
Trial details
- NCT number
- NCT05630066
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-27
- Primary completion
- 2025-12-02
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.